{
    "clinical_study": {
        "@rank": "18373", 
        "arm_group": [
            {
                "arm_group_label": "CC-292 375mg", 
                "arm_group_type": "Experimental", 
                "description": "Treatment"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Control"
            }
        ], 
        "brief_summary": {
            "textblock": "CC-292 is an oral agent that is under clinical development for the treatment of rheumatoid\n      arthritis an autoimmune inflammatory disorder.\n\n      This study will test the clinical effectiveness and safety of an orally (PO) administered\n      dose of CC-292 compared to placebo in US female patients currently on background\n      Methotrexate (MTX) with active Rheumatoid Arthritis (RA"
        }, 
        "brief_title": "Efficacy and Safety Study of CC-292 Versus Placebo as Co-therapy With Methotrexate in Active Rheumatoid Arthritis", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled,\n      proof-of-concept study to determine the efficacy and safety of CC-292 (375 mg PO daily) on a\n      stable background of MTX therapy in female subjects with active RA.\n\n      Approximately 80 female subjects with active RA will be randomized 1:1 into two dose groups:\n      active CC-292 (375 mg PO daily) or identically-appearing placebo capsules for 4 weeks"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Female between 18 and 80 years of age (inclusive) at the time of signing the informed\n             consent.\n\n        Must meet the 2010 American College of Rheumatology/ European League Against Rheumatism (\n        ACR/EULAR) Classification Criteria for rheumatoid arthritis  and have rheumatoid arthritis\n        for at least 6 months.\n\n          -  Must continue to have active rheumatoid arthritis  at the time of randomization\n\n          -  Must have been treated with methotrexate (MTX) for at least 4 months prior to\n             randomization, and must be on a stable dose between 7.5 and 25 mg/week (PO or\n             parenteral, not both) for at least 12 weeks prior to randomization.\n\n          -  Must be receiving rheumatoid arthritis treatment on an outpatient basis.\n\n          -  Must have more than or equal to 6 swollen joints (out of 66 joint counts) at\n             randomization (Visit 2).\n\n          -  Must have more than or equal to 6 tender joints (out of 68 joint counts) at\n             randomization (Visit 2).\n\n          -  Must be positive for Rheumatoid factor (RF) and and have at least two of the\n             following laboratory measures: High-sensitivity C-reactive Protein  (hsCRP) greater\n             than or equal to 10 mg/L, erythrocyte sedimentation rate > 28 mm after the first 1\n             hour, positive for anti-Cyclic Citrullinated Peptide Antibody ( CCP)\n\n          -  Subject must meet the lab criteria for Serum Chemistry, Hematology, Immunology and\n             Urinalysis\n\n          -  Subject must be on oral folate supplementation or Leucovorin dose of 5mg/week while\n             on MTX\n\n          -  Subjects meeting the Hepatitis B criteria indicating the absence of current infection\n             are eligible to participate.\n\n          -  Subjects must be negative for Hepatitis C antibody\n\n        Current Medications\n\n          -  Must have been treated with methotrexate  for at least 4 months prior to\n             randomization, and must be on a stable dose for at least 12 weeks prior to\n             randomization.\n\n          -  Sulfasalazine and Hydroxychloroquine are allowed, however subject must be on stable\n             dose for at least 12 weeks prior to randomization and through Day 28/Week 4 of the\n             study.\n\n          -  Nonsteroidal anti-inflammatory drugs ( NSAIDs) and pain medications are allowed ,\n             however, subject must be on a stable regimen for at least 7 days prior to\n             randomization and through Day 28/Week 4 of the study.\n\n          -  Oral corticosteroids are allowed, however subject  must be on a stable dose of\n             prednisone less than or equal to 10 mg/day or equivalent for at least 28 days prior\n             to randomization and through Day 28/Week 4 of the study.\n\n        Contraception Requirement\n\n        - Females of childbearing potential (FCBP) must have a negative pregnancy test at\n        Screening and Baseline.  FCBP subjects must use 2 forms of contraception simultaneously\n        while on investigational product (IP) and for at least 28 days after taking the last dose\n        of IP.\n\n        Exclusion Criteria:\n\n          -  Male participants\n\n          -  Major surgery (including joint surgery) within 8 weeks prior to screening or planned\n             major surgery within 6 months following randomization.\n\n          -  Autoimmune disease other than RA\n\n          -  Pregnant or nursing women\n\n          -  History or Concomitant Cardiac, Nervous System, Psychiatric, Pulmonary, Renal,\n             Hepatic, Endocrine, Gastrointestinal or Ocular disease, Solid tumors and hematologic\n             malignancies.\n\n          -  Positive tuberculosis (TB) test at screening.\n\n          -  History of alcohol, drug or chemical abuse.\n\n          -  Any condition that could affect CC-292 absorption, including gastric restrictions,\n             bariatric surgery, such as gastric bypass, and clinical conditions that are\n             associated with decreased intragastric acid production such as acid pernicious\n             anemia."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01975610", 
            "org_study_id": "CC-292-RA-001"
        }, 
        "intervention": [
            {
                "arm_group_label": "CC-292 375mg", 
                "description": "375 mg PO daily (250 mg in the AM and 125 mg in the PM for 28 days)", 
                "intervention_name": "CC-292", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Twice daily for 28 days", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Methotrexate"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Arthritis, Rheumatoid, Autoimmune, Inflammatory, Synovial, Bruton's tyrosine kinase (Btk), CC-292, Joint Disease", 
        "lastchanged_date": "June 3, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35216"
                    }, 
                    "name": "Achieve Clinical Research LLC"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Phoenix", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85037:"
                    }, 
                    "name": "Arizona Arthritis Research"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hot Springs", 
                        "country": "United States", 
                        "state": "Arkansas", 
                        "zip": "71913"
                    }, 
                    "name": "Generations Medical Research"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90025"
                    }, 
                    "name": "UCLA David Geffen School of Medicine"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Palm Desert", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92260"
                    }, 
                    "name": "Desert Medical Advances"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Poway", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92064"
                    }, 
                    "name": "Arthritis Care and Research Center, Inc."
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bridgeport", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "06606"
                    }, 
                    "name": "Joao Nascimento MD"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gainesville", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32607"
                    }, 
                    "name": "Southeastern Integrated Medical"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jupiter", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33458"
                    }, 
                    "name": "Family Arthritis Center"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Port Richey", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "34652"
                    }, 
                    "name": "Suncoast Clinical Research"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ocala", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "34474"
                    }, 
                    "name": "Ocala Rheumatology Research Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbia", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21045"
                    }, 
                    "name": "Columbia Medical Practice"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Worcester", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "01605"
                    }, 
                    "name": "Clinical Pharmacology Study Groups"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kalamazoo", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "49048:"
                    }, 
                    "name": "Borgess Research Institute"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "26301"
                    }, 
                    "name": "NYU Langone Medical Center"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oklahoma City", 
                        "country": "United States", 
                        "state": "Oklahoma", 
                        "zip": "73112"
                    }, 
                    "name": "Lynn Health Science Institute"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Duncansville", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "16635"
                    }, 
                    "name": "Altoona Center for Clinical Research"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Charleston", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29425"
                    }, 
                    "name": "Medical University of South Carolina"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rock Hill", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29732"
                    }, 
                    "name": "PMG Research of Charlotte"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jackson", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "38305"
                    }, 
                    "name": "West Tennessee Research Institute"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Memphis", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "38119"
                    }, 
                    "name": "Ramesh C. Gupta, MD"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Austin", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78731"
                    }, 
                    "name": "Austin Regional Clinic"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77070"
                    }, 
                    "name": "Rheumatology Clinic of Houston"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Clarksburg", 
                        "country": "United States", 
                        "state": "West Virginia", 
                        "zip": "26301"
                    }, 
                    "name": "Mountain State Clinical Research"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Onalaska", 
                        "country": "United States", 
                        "state": "Wisconsin", 
                        "zip": "54650"
                    }, 
                    "name": "Gundersen Clinic Ltd"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 2a, 4-Week Double-Blind, Proof-of-Concept Efficacy and Safety Study of CC-292 Versus Placebo as Co-therapy With Methotrexate in Active Rheumatoid Arthritis", 
        "overall_contact": {
            "email": "mawadalla@celgene.com", 
            "last_name": "Mark Adwalla, M.S.", 
            "phone": "732-652-6170"
        }, 
        "overall_contact_backup": {
            "email": "dsutherland@celgene.com", 
            "last_name": "Donna Sutherland, B.A., MLT/ASCP", 
            "phone": "732-652-6486"
        }, 
        "overall_official": {
            "affiliation": "Celgene Corporation", 
            "last_name": "Yufang Lu, M.D.", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Proportion of subjects who achieve the ACR 20", 
            "measure": "American College of Rheumatology Criteria for a 20% improvement (ACR 20)", 
            "safety_issue": "No", 
            "time_frame": "Week 4"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01975610"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Safety and tolerability of CC-292 (375 mg PO daily) compared with placebo in subjects on a background of stable MTX therapy.", 
                "measure": "Number of participants with adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 8 Weeks"
            }, 
            {
                "description": "Proportion of subjects who achieve the ACR 50", 
                "measure": "American College of Rheumatology Criteria for a 50% improvement (ACR 50)", 
                "safety_issue": "No", 
                "time_frame": "Week 4"
            }, 
            {
                "description": "Proportion of subjects who achieve the ACR 70", 
                "measure": "American College of Rheumatology Criteria for a 70% improvement (ACR 70)", 
                "safety_issue": "No", 
                "time_frame": "Week 4"
            }
        ], 
        "source": "Celgene Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Celgene Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}